Form D · Other Health Care
Visgo Therapeutics, Inc.
Burlington, MA · CIK 0001635772
Offering snapshot reported Mar 9, 2015 · SEC filing
- Reported sold
- $725K Offering amount: $1.1M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 25, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 9, 2015 | Initial | $725,349 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-235448
Source: Form D, filed Mar 9, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeanne Bertonis | Director, Executive |
| Pamela Hay | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
67 South Bedford Street Suite 400 W
Burlington, MA, 01803
Burlington, MA, 01803